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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked reces-
sive muscle-wasting disease, characterized by progressive 
weakening of skeletal, respiratory, and cardiac muscle fol-
lowed by necrosis and fibrosis. DMD affects ~1:3,500 live 
male births and is associated with delayed motor milestones. 
Affected individuals commonly lose ambulation before the 
age of 13 years and most will die in their third decade due 
to respiratory and cardiac complications.1–3 DMD occurs as a 
result of mutations within the DMD, located on chromosome 
Xp21.2, that lead to premature termination of translation. 
Mutations have been observed across all 79 exons of this 
2.4 Mb gene, the most frequent type being exonic deletions 
and duplications that induce a frame-shift in the protein-cod-
ing sequence. Therefore, expression of the 427 kDa muscle-
specific dystrophin isoform is ablated, severely compromising 
the link between the myofiber sarcolemma and cytoskeletal 
actin, essential for maintaining muscle fiber integrity during 
contraction and relaxation.4
An allelic disorder, Becker muscular dystrophy (BMD), also 
arises from mutations in the DMD, and these are most com-
monly in-frame deletions that lead to synthesis of an inter-
nally deleted dystrophin isoform that retains some function. 
BMD patients exhibit a later age of onset, slower clinical pro-
gression, and a longer lifespan compared to DMD. In some 
cases the phenotype may be so mild that diagnosis is only 
made late in life or by chance.5,6 The variation in disease pro-
gression and severity between DMD and BMD provide the 
theoretical underpinnings for therapeutic approaches such 
as antisense oligomer (AO)-induced exon skipping, the goal 
being to modulate processing of the defective DMD transcript 
to express a BMD-like dystrophin isoform7–9 that would result 
in a less severe phenotype.
Duplications account for ~5–10% of all reported mutations 
in DMD in the Leiden database,10 although the incidence has 
been reported to be higher in other databases and regis-
tries.11 Regardless of the exact figure, the number of DMD 
patients with duplications is substantial and demands the 
development of effective treatment strategies for this class 
of mutation. Furthermore, restoration of the reading frame 
for some duplications by excising one copy of a single exon 
duplication could permit expression of a normal dystrophin 
transcript. This could potentially allow synthesis of a normal 
dystrophin isoform, in contrast to restoring the reading frame 
around the more common deletions where only a BMD-like 
isoform can be generated.
Induced exon skipping is an intervention during dystrophin 
pre-mRNA splicing, based on the principle that removing one 
or more targeted exons can either remove or bypass pro-
tein truncating mutations and allow synthesis of internally 
deleted, but semifunctional BMD-like dystrophin isoforms.12,13 
Exon skipping can restore the reading frame around dys-
trophin genomic deletions, the most common type of DMD 
lesion, or induce excision of a single in-frame exon to remove 
an intraexonic protein truncating mutation.7,14 However, the 
capacity of exon-skipping strategies to correct dystrophin 
duplications has not been extensively explored. Here, we 
report studies on targeted excision of dystrophin exon 2, the 
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Duchenne muscular dystrophy is a severe muscle-wasting disease caused by mutations in the dystrophin gene that ablate 
functional protein expression. Although exonic deletions are the most common Duchenne muscular dystrophy lesion, 
duplications account for 10–15% of reported disease-causing mutations, and exon 2 is the most commonly duplicated exon. 
Here, we describe the in vitro evaluation of phosphorodiamidate morpholino oligomers coupled to a cell-penetrating peptide 
and 2′-O-methyl phosphorothioate oligonucleotides, using three distinct strategies to reframe the dystrophin transcript in 
patient cells carrying an exon 2 duplication. Differences in exon-skipping efficiencies in vitro were observed between oligomer 
analogues of the same sequence, with the phosphorodiamidate morpholino oligomer coupled to a cell-penetrating peptide 
proving the most effective. Differences in exon 2 excision efficiency between normal and exon 2 duplication cells, were apparent, 
indicating that exon context influences oligomer-induced splice switching. Skipping of a single copy of exon 2 was induced in 
the cells carrying an exon 2 duplication, the simplest strategy to restore the reading frame and generate a normal dystrophin 
transcript. In contrast, multiexon skipping of exons 2–7 to generate a Becker muscular dystrophy-like dystrophin transcript was 
more challenging and could only be induced efficiently with the phosphorodiamidate morpholino oligomer chemistry.
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most commonly duplicated exon in DMD.10 By-passing the 
protein truncating mutation arising from exon 2 duplication 
can in theory be achieved by applying three distinct strate-
gies: (i) excise only one of the duplicated exons; (ii) remove 
both duplicated exons and induce the reinitiation of transla-
tion in exon 3 or 6,15,16 or (iii) remove both duplicated exons, in 
addition to exons 3, 4, 5, 6, and 7 to restore the reading frame 
of the modified dystrophin transcript. We show that single 
exon 2 skipping can be induced in a dose-dependent manner 
and that the selection of splice switching oligomer chemistry 
has a major influence on splice-switching efficiency.
Results
The simplest and preferable strategy would be to remove 
just one copy of the duplicated exon, resulting in a full-length 
dystrophin transcript that encodes the normal protein. If both 
copies of exon 2 were removed from the dystrophin mRNA, 
then it is possible that reinitiation of translation could occur 
in exons 3 or 6 (Figure 1a).15,16 Should single exon skipping 
prove unfeasible, or reinitiation of translation proves ineffi-
cient from skipping both exon 2s, the alternate exon-skipping 
strategy would be to excise exons 2–7 (Figure 1b).
The coding sequence for exon 2 in the dystrophin mRNA, 
along with 25 bases of the flanking intronic sequences was 
interrogated by ESE Finder 3.0 to predict motifs involved in 
processing the dystrophin pre-mRNA. AOs were designed 
to anneal to the known splice sites and predicted enhancer 
motifs across exon 2 and flanking intronic sequences 
(Figure 2). All oligomer sequences (Table 1) were first evalu-
ated as 2′O methyl phosphorothioate oligomers (2OMe AO) 
after transfection into normal human myogenic cells, and 
only showed modest or no target exon exclusion from the 
transcript (data images not shown, densitometry results 
summarized in Table 1). One of the more promising com-
pounds, AO H2A(+12+41) induced minimal exon 2 skipping 
(Figure 3a). There were indications of dose-dependent exon 
skipping at AO transfection concentrations between 1 and 50 
nmol/l, but robust exon 2 skipping was not induced, even at 
the high AO concentrations. Nonoverlapping AOs were com-
bined into cocktails of two or more compounds and trans-
fected into cultured normal cells, but there was no increase 
in exon-skipping efficiencies relative to that induced by the 
single compounds (data not shown).
All the 2OMe AOs targeting exon 2 were tested in two 
unrelated myogenic dystrophic cell strains, DMD 2173 and 
DMD 2174, both carrying duplications of dystrophin exon 2. 
Again, H2A(+12+41) was the most effective AO at inducing 
exon 2 skipping in both cell strains, with induction of dystro-
phin transcripts missing one or both copies of exon 2, albeit 
at levels not substantially higher than that induced in the nor-
mal cells (Figure 3b). Other 2OMe AOs targeting exon 2 did 
not induce exon skipping or resulted in less than 5% exon 2 
skipping in these patient cells, and therefore were excluded 
from further studies (data not shown). Cocktails containing all 
possible combinations of two or more nonoverlapping AOs, 
targeting exon 2, were transfected into both cell strains, but 
this did not lead to improved skipping compared to a single 
2OMe AO (data not shown).
H2A(+12+41) was synthesized as a phosphorodiamidate 
morpholino oligomer, coupled to a cell-penetrating peptide 
(PPMO), and transfected into normal human myogenic cells. 
Robust skipping of exon 2 was achieved, with >80% efficiency 
at concentrations of 250 nmol/l and above (Figure 3c). When 
Figure 1 AO strategies to restore dystrophin expression in the 
presence of a frame-shifting exon 2 duplication. (a) Possible 
outcomes resulting from targeting of exon 2 only include single exon 
skipping (and a resultant in-frame transcript) or excising both copies 
of exon 2 and relying on reinitiation of translation from exon 3 or 6. 
(b) Induction of multiple exon skipping targeting exons 2–7 to restore 
the reading frame. AO, antisense oligomer.
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Figure 2 Schematic showing predicted SR proteins binding 
motifs in dystrophin exon 2, with AO annealing sites indicated. 
Lower case letters indicates intronic sequences, while the exon is 
shown in upper case. The colored bars represent different motifs 
for predicted SR binding proteins. The heights of the bars indicate 
predicted binding strength. Red: SRSF1; purple: SRSF1 (IgM-
BRCA1); green: SRSF5; yellow: SRSF6. AO, antisense oligomer; 














Exon Skipping for Dystrophin Exon 2 Duplications
Greer et al.
3
transfected into the DMD cell strains, this PPMO induced 
consistent and robust exon skipping, and dystrophin tran-
scripts missing one or both copies of exon 2 were induced in 
a dose-dependent manner (Figure 3d). Both DMD 2173 and 
DMD 2174 showed similar effects after PPMO transfection, 
with one or both of the duplicated exons being removed in 
a dose-dependent manner, at concentrations similar to that 
required to excise exon 2 from the normal dystrophin tran-
script. Exon skipping of only one of the duplicated exons was 
also induced in a dose-dependent manner and was readily 
apparent after transfection at PPMO concentrations of 100–
600 nmol/l (Figure 3d).
As another splice-switching strategy, we investigated mul-
tiple exon skipping to excise exons 2–7 as a single block, 
the minimal rearrangement necessary to induce an in-frame 
transcript in lieu of skipping a single copy of exon 2. Exons 
2–7 were targeted for removal by AOs (Table 2) previously 
optimized for single exon skipping,17 combined in equimolar 
amounts and transfected into normal- and patient-derived 
cells. 2OMe AOs transfected as cationic lipoplexes were 
unable to induce consistent removal of the exon 2–7 block 
from the full-length transcript, with many intermediate prod-
ucts present and an apparent ablation of the full-length tran-
script after transfections of 50 nmol/l and above in normal 
cells (Figure 4a), or 200 nmol/l and above in patient-derived 
cells (Figure 4a,b).
In contrast, efficient multiple exon skipping was 
induced using the same oligomer sequence combinations 
Table 1 Nucleotide sequences, annealing coordinates, GC content, and 
exon-skipping efficiency (percentage of shortened product relative to full-
length amplicon) of 2OMe AOs designed to remove dystrophin exon 2 after 






H2A(−14 + 10) UCUCUUUCAUCUAAAAUGCAAAAU 25 0














H2D(+03−21) AAAGUAACAAACCAUUCUUACCUU 29 0
AO, antisense oligomer; 2OMe, 2′O methyl phosphorothioate oligomers; 
GC, guanine-cytosine content.
Figure 3 AO-induced excision of dystrophin exon 2 from normal human myogenic cells and patient dystrophin myogenic cells 
with a duplication of exon 2, using oligomers of the 2OMe and PPMO chemistries. Myogenic cells were either transfected with 2OMe 
AO:cationic lipoplexes at the concentrations indicated and incubated for 24 hours, or transfected with PPMOs and incubated for 96 hours. Total 
RNA was extracted and nested reverse-transcriptase PCR was undertaken across exons 1–4. The normal, full length, and exon 2-deleted 
products are 389, 451, and 327 bp, respectively. (a) Normal human myogenic cells transfected with 2OMe; (b) exon 2 duplication cells 
with 2OMe; (c) normal human myogenic cells with PPMO; (d) exon 2 duplication cells with PPMO; (e) sequence chromatogram showing 
exon 1 being spliced to exon 3; (f) schematic indicating exonic combinations and predicted amplicon size. AO, antisense oligomer; PPMO, 
phosphorodiamidate morpholino oligomer, coupled to a cell-penetrating peptide; UT: amplicon from untreated exon 2 duplication cells; +ve: 
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administered as PPMOs. Exons 2–7 were removed effi-
ciently in a dose-dependent manner, with a corresponding 
depletion of the full-length transcript product in both nor-
mal- and patient-derived cells. Ablation of the full-length tran-
script was complete after transfection of normal cells at total 
combined oligonucleotide concentrations of 250 nmol/l and 
above, while higher concentrations were needed to modify 
the expression of the exon 2 duplicated dystrophin isoform 
(Figure 4c,d). A 410 bp amplicon was observed in several 
lanes and this was found to represent sporadic exon 9 skipping 
in addition to multiexon skipping of exons 2–7. Sporadic exon 
9 skipping has been reported previously and does not disrupt 
the reading frame.18 A smaller amplicon of 228 bp was also 
observed and found to represent the removal of exons 2–9 
a transcript that has also been reported previously, and was 
detected in untreated normal and patient cells.19 The identity 
of the 539 and 228 bp amplicons can be deduced from the 
sequence chromatogram shown in Figure 4e. Normally, a 
mixed sequence chromatogram would require purified tem-
plates, but in this case, the sequence was unambiguous to 
the end of exon 1 and then mixed peaks could easily be read 
to identify the start of exons 8 or 10.
Discussion
Every dystrophin exon, excluding the first and last can be 
excised from the mature gene transcript, albeit with consider-
able variation in the efficiency of exon removal.17 Dystrophin 
exon 2 is relatively small, consisting of only 62 nucleotides 
and is flanked by introns 1 and 2 of 82,853 and 170,318 
bases, respectively. The short length of exon 2 allowed the 
exon to be covered with a few oligonucleotides. H2A(−14+10), 
Table 2 Nucleotide sequences and annealing coordinates of AOs de-









Figure 4 Induced removal of dystrophin exons 2–7 from normal human myogenic and exon 2 duplication myogenic cells using 
2OMe AO and PPMO cocktails. Primary human and dystrophic myogenic cell cultures were transfected with either 2OMeAO:cationic 
lipoplexes at the concentrations indicated and incubated for 24 hours or transfected with PPMO conjugates targeting dystrophin exons 2–7 
and left for 96 hours. Total RNA was extracted and nested RT-PCR was undertaken across exons 1–10. The normal, full length, and exon 
2–7 deletion transcripts are represented by products of 1,157, 1,219, and 539 bp, respectively. (a) Normal myogenic cells treated with the 
2OMe cocktail. (b) Exon 2 duplication cells treated with the 2OMe cocktail. (c) Normal myogenic cells treated with the PPMO cocktail. (d) 
Exon 2 duplication cells treated with the PPMO cocktail. (e) Sequence chromatogram confirming identity of 539 and 210 bp amplicons. Mixed 
sequencing peaks are generated downstream of exon 1 due to templates representing transcripts missing exons 2–7 and 2–9. (f) Schematic 
indicating induced exon-skipping product sizes. AO, antisense oligomer; PPMO, phosphorodiamidate morpholino oligomer, coupled to a cell-
penetrating peptide; UT: amplicon from untreated exon 2 duplication cells; +ve: amplicon from untreated normal cells; −ve: no template PCR 
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H2A(+12+41), and H2A(+19−11) were designed to target 
exon 2 with H2A(+12+41) inducing the highest level of exon 
skipping. Subsequent overlapping AOs were designed based 
primarily on H2A(+12+41), but no significant improvements 
in AO efficiency were apparent, as assessed after transfec-
tion in normal myogenic cells, and therefore, further studies 
focused on the H2A(+12+41).
The application of AO-induced exon skipping to correct 
duplications has to date been minimal, and we are aware of 
only two studies investigating practical exon skipping to cor-
rect duplications in DMD. We have described the correction 
of an exon 18 duplication by excising both copies of exon 18, 
as well as exon 17,14 whereas Aartsma-Rus et al.7 have dem-
onstrated successful skipping of duplicated exons 44 and 45, 
but did not achieve skipping of a larger duplication involv-
ing exons 52–62. Here, we sought to address duplications of 
exon 2, the most frequently duplicated exon in DMD.
Technically, three distinct exon-skipping strategies could 
be used to induce functional dystrophin expression in cells 
from patients with duplications of exon 2. The simplest and 
preferable strategy would be to remove just a single copy 
of exon 2 from the DMD transcript, as this would result in 
a normal dystrophin transcript and protein. The removal of 
a single exon 2 from patient cells was achieved by select-
ing a combination of AO sequence, AO chemistry, and titra-
tion of the AO, with PPMOs consistently proving to be more 
effective than the 2OMe AOs at the removal of exon 2. Direct 
comparisons between the two different oligomer chemistries 
are challenging, as the transfection methods vary, but we 
sought to undertake the 2OMe AO and PPMO evaluations 
at transfection concentration ranges where dose-dependent 
exon skipping was evident. The 2OMe AOs are efficiently 
delivered to cells in vitro when complexed to a cationic lipo-
some, but we have found that these lipoplexes can be toxic 
to the cells at concentrations above 600 nmol/l. PPMOs have 
a neutral backbone and cannot be complexed with cationic 
liposomes, but the presence of the cell-penetrating peptide 
enhances uptake.
We previously reported that AO sequences optimized as 
2OMe AO compounds were similarly effective when tested 
as phosphorodiamidate morpholino oligmers.20 However, 
here, we report substantial differences in in vitro exon skip-
ping efficiency between 2OMe AOs, and PPMOs. The PPMO 
H2A(+12+41) induced very efficient skipping of both copies 
of exon 2 in normal- and patient-derived cells, suggesting 
that this compound may be effective in removing a single 
exon 2 after transfection at lower concentrations. Higher 
oligomer concentrations removed both copies of exon 2 in 
vitro, and while the resulting dystrophin transcript is out-of-
frame, it is possible that dystrophin could still be synthesized 
through reinitiation of translation in exon 6.15 Whether trans-
lation reinitiation in exon 6 occurs in these patient cells after 
removal of both copies of exon 2 is yet to be confirmed. We 
were unable to demonstrate dystrophin expression by west-
ern blotting in treated patient cells where robust skipping of 
both copies of exon 2 was induced. However, this was not 
unexpected, since the DMD patient cells used in these exper-
iments were derived from skin fibroblasts and forced into 
myogenic lineage with a MyoD expressing adenovirus. While 
the myogenic capacity of such cells is generally sufficient for 
RNA-based studies, the process is not efficient and detection 
of dystrophin from normal skin fibroblasts treated in this man-
ner is technically difficult. Nevertheless, protein translation 
reinitiation has been reported in patients carrying nonsense 
and frame-shifting mutations in exons 115 and 2.21 It is pos-
sible that some dystrophin is produced, despite the frame-
shifting exclusion of exon 2, but at levels below that detected 
by our assays.
A technically more challenging alternative strategy to sin-
gle exon 2 skipping, or dual exon skipping and reinitiation 
of translation was to remove exons 2–7. Although we have 
previously achieved skipping of seven consecutive exons 
(20–26) in the mdx mouse22 after transfection with 2OMe 
AOs, we were not able to achieve skipping of the six con-
secutive exons (2–7) from the human dystrophin transcript 
with the same oligomer chemistry. We had previously shown 
that combining individually optimized 2OMe AOs does not 
necessarily result in the most efficient multiexon skipping 
cocktails20 and we have also observed that some exon com-
binations are easier to skip than others (unpublished data). 
However, when the same oligomer sequences, prepared as 
PPMOs were transfected into normal- and patient-derived 
cells, robust exon skipping of the target exon block was 
achieved in a dose-dependent manner. Remarkably, the 
multiexon skipping appeared very efficient with the PPMO 
chemistry. Although PPMO concentrations of 250 nmol/l or 
higher were needed for robust skipping of exons 2–7 in nor-
mal cells, this is the combined concentration of the seven 
oligomers, which are present at individual concentrations of 
<30 nmol/l, whereas one copy of exon 2 was skipped in 28% 
of the total transcript products, as assessed by densitometry, 
after transfection with the single PPMO targeting exon 2 at a 
concentration of 100 nmol/l in normal cells. Hence, it would 
appear that multiple exon skipping induced by PPMOs may 
not require proportionally higher concentrations of oligomers 
and the indications are that there is some synergy between 
the oligomers that may weaken selection of the block of tar-
geted exons. Further work is needed to confirm this obser-
vation and establish whether the phenomenon is restricted 
to certain domains of the dystrophin gene transcript. Never-
theless, this study does give some hope that a cocktail of 
splice-switching oligomers may be a viable option to address 
clustered DMD-causing mutations.
Evidence suggests that removal of exons 2–7 may result in 
a functional dystrophin isoform, capable of reducing the sever-
ity of DMD. According to Banks et al.23, loss of the N-terminal 
domain leads to a mild BMD phenotype and patients with 
deletions of exons 3–7 commonly present with low-level basal 
dystrophin and an intermediate phenotype.19,24,25 Mutations in 
this region are described as “leaky”, and patient cells, missing 
dystrophin exons 3–7 and 5–7, that were treated in vitro with 
AOs targeting exon 8 to restore the reading frame express 
dystrophin that was readily detectable by western blotting.26
In summary, in developing antisense strategies to over-
come mutations in the DMD, it is evident that the AO chem-
istry, annealing target and concentration are crucial factors 
in determining splice-switching efficacy. This is equally rel-
evant not only for patients with exon 2 duplications but also 
for patients with all dystrophin mutations. Consistent with our 
previous studies, we find the PPMO chemistry to be better 
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suited for splice-switching oligomers to address duplications 
and induce multiexon skipping in vitro. The current Eteplirsen 
clinical trials are showing great promise27 and these studies 
indicate the applicability of this oligomer chemistry to other 
DMD lesions, in particular duplications.
Materials and methods
AO design and synthesis. Splice-switching AOs were 
designed to anneal to splicing motifs at the intron:exon 
boundaries, as well as exon splice enhancer (ESE) motifs 
as predicted by the web-based application, ESEfinder.28 
2OMe AOs were prepared on an Expedite 8909 Nucleic acid 
synthesizer (Applied Biosystems) using the 1 μmol/l thioate 
synthesis protocol. PPMOs were supplied by Sarepta Thera-
peutics (Cambridge, MA). Oligomer nomenclature is based 
on that described by Mann et al.8 and indicates oligomer 
annealing coordinates.
Cell propagation. Normal primary human myoblasts were 
cultured from surplus biopsy material taken from healthy 
individuals during elective surgery at Royal Perth Hospital, 
Perth, Western Australia. Informed consent was obtained 
and the project was approved by the Human Ethics Commit-
tee of the University of Western Australia (approval number, 
RA4/100/2295). Primary human myogenic cells were pre-
pared as described by Rando and Blau29 with minor modifi-
cations,30 and grown in Hams F10 (Gibco; Life Technologies, 
Melbourne, Australia) supplemented with fetal bovine serum 
(Serana, Bunbury, Australia) and chick embryo extract (US 
Biological, Swampscott, MA). Primary fibroblasts were 
derived from skin biopsies taken, after informed consent, 
from DMD patients with frame-shifting duplications of only 
exon 2 in the dystrophin gene (Newcastle University ethics 
approval number 08/H0906/28+5).
Prior to transfection, patient fibroblasts were induced in 
to the myogenic lineage with a MyoD expressing adenovi-
rus, Ad5.f50.AdApt.MyoD (Native Antigen Company, Oxford, 
UK),31 at an multiplicity of infection of 200 and allowed to dif-
ferentiate in 5% horse serum (Gibco; Life Technologies) in 
Dulbecco’s modified Eagle medium (Life Technologies) for 72 
hours. Cells were seeded at 3 × 104 per well in 24-well plates 
that had been sequentially pretreated for 1 hour with 50 μg/
ml poly d-Lysine (Sigma, Sydney, Australia) and 100 μg/ml 
Matrigel (BD Biosciences, Sydney, Australia).26
Transfection. Myogenic cells were transfected with either 
2OMe AO Lipofectamine 2000 (L2K; Life Technologies) lipo-
plexes at a 1:1 ratio in Opti-MEM (Life Technologies) accord-
ing to the manufacturer’s instructions, or PPMO in Opti-MEM. 
The media was replaced after ~24 hours for 2OMe AO trans-
fections, or after 96 hours for PPMO transfections.
RNA extraction and RT-PCR assays. Trizol (Life Technolo-
gies) was used to extract total RNA from cultured cells, 
according to the manufacturer’s guidelines. RT-PCR primers 
were designed to amplify several exons either side of the 
target exons, in order to minimize preferential amplification 
of shortened (skipped) transcript products. This assay also 
allows detection of other RNA processing events, including 
cryptic splice site activation or removal of nontargeted exons. 
Primer sequences for cDNA synthesis and amplification are 
shown in Table 3.
RT-PCR was performed on 50 ng of total RNA using a 
Superscript III One-Step RT-PCR System with Platinum Taq 
DNA Polymerase (Life Technologies) as described by Wilton 
et al.17 After 35 cycles, a 1-μl aliquot was removed and used 
as template in a nested PCR for 30 cycles using AmpliTaq 
Gold (Applied Biosystems, Melbourne, Australia).
Gel analysis and Imaging. RT-PCR products were resolved 
on a 2% agarose gel in Tris-acetate EDTA buffer using a 
100 bp DNA ladder (Life Technologies) as size standards. 
Exon-skipping efficiency was estimated by analyzing den-
sitometry images captured by a Chemi-Smart 3000 sys-
tem (Vilber Lourmat) using Chemi-Capt software for image 
acquisition and Bio-1D software for analysis, as described 
 previously.20 All transfections and RT-PCR analyses were 
carried out in duplicate.
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